Get the Stockscreener App
2.65
4.33%
0.11
After Hours:
2.68
0.03
+1.13%
Ventyx Biosciences Inc stock is traded at $2.65, with a volume of 2.27M.
It is up +4.33% in the last 24 hours and up +21.56% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$2.54
Open:
$2.53
24h Volume:
2.27M
Relative Volume:
1.79
Market Cap:
$184.20M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.9464
EPS:
-2.8
Net Cash Flow:
$-167.04M
1W Performance:
+54.07%
1M Performance:
+21.56%
6M Performance:
-39.36%
1Y Performance:
+12.29%
1-Day Range:
$2.41
$2.75
1-Week Range:
$1.67
$2.75
52-Week Range:
$1.67
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.65 | 184.20M | 0 | -192.96M | -167.04M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey
Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Nigeria
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat
Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com
Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times
Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News
Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News
Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex
Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN
Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat
Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle
Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News
Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com
Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ventyx Biosciences Inc Stock (VTYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Nov 22 '24 |
Buy |
1.83 |
238,248 |
434,946 |
1,913,276 |
| Mohan Raju | CEO AND PRESIDENT |
Jun 10 '24 |
Option Exercise |
0.20 |
96,778 |
19,356 |
1,675,028 |
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
284,999 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
264,998 |
| Mohan Raju | CEO AND PRESIDENT |
Apr 02 '24 |
Sale |
5.40 |
4,312 |
23,299 |
1,578,250 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,405 |
7,592 |
24,303 |
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
286,650 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
25,708 |
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '24 |
Option Exercise |
0.00 |
11,843 |
0 |
1,582,562 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
266,649 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):